RxDoctor Payments Data

Thomas Pearson, MD

Neurology · Palm Harbor, FLNPI 1144204124

Payments from drug & device makers

$151,112in general payments, 2019–2025

Across 606 payments — averaging $249.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$137K
  • MDD US Operations, LLC$6K
  • Idorsia Pharmaceuticals US Inc$1K
  • Pfizer$503
  • Neurocrine Biosciences, Inc.$466
  • Eisai Inc.$456
  • plus $5K from 33 others

What the payments were for

  • Consulting fees$2,5502%
  • Speaking & faculty fees$129,68986%
  • Travel & lodging$7,2145%
  • Food & beverage$11,5458%
  • Education$1150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$151,112 in reported general payments places this provider in the 85th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida

Medicare billing

Part B allowed, 2024
$415,983
Medicare patients
545
Services billed
2,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate14$25,724
QuliptaAtogepant16$16,813
NamzaricMemantine Hcl/Donepezil Hcl13$16,644
AptiomEslicarbazepine Acetate13$16,121
FycompaPerampanel11$11,702
RivastigmineRivastigmine Tartrate81$6,427
Donepezil Hcl210$4,572
DayvigoLemborexant13$4,224
Carbidopa-LevodopaCarbidopa/Levodopa112$4,197
Entacapone17$2,999
Levetiracetam54$2,432
Memantine Hcl56$1,509
Gabapentin56$1,486
Oxcarbazepine14$1,407
Eletriptan HbrEletriptan Hydrobromide19$1,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieQulipta, Namzaric$137,168$33,45629 claims
PfizerNurtec Odt$503$25,72414 claims
Sunovion Pharmaceuticals Inc.Aptiom$441$16,12113 claims
Eisai Inc.Fycompa, Dayvigo$456$15,92624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,434 neurology providers in Florida.

Other neurology in Palm Harbor

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →